Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
BackgroundInsulin is the primary treatment for type 1 and some type 2 diabetes but remains costly in the United States, even though it was discovered more than a century ago.High prices can lead to nonadherence and are often sustained by patents and regulatory exclusivities that limit competition on brand-name products.We sought to examine how manu